Oncolytics Biotech Announces the Presentation of REOLYSIN Clinical Data

Oncolytics Biotech (TSX:ONC; OTCQX:ONCYF) announced the presentation of two posters on REOLYSIN at the European Society for Medical Oncology.
As quoted in the press release:

“Our poster on pooled data outlines the largest safety database available to date for an oncolytic virus and demonstrates that REOLYSIN is safe and well tolerated when administered in combination with chemotherapy,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “Regarding the metastatic breast cancer data presented within this pooled safety data, further analysis of our phase two study highlights a doubling of overall survival benefit for patients with hormone receptor double-positive, HER2-negative breast cancer – a major genetic subgroup – when treated with REOLYSIN/paclitaxel combination treatment versus paclitaxel alone.

Click here to read the full press release.

Source: www.newswire.ca